Westhouse purchased the US and UK patents for the Profemme breast cancer screening technology for £500,000 from the Battlebridge Group.

Westhouse consists of two divisions including Services and Devices that develops breast cancer screening technology.

The breast cancer screening device utilizes thermometry-based technology to measure temperature differences in breast tissue indicating any abnormalities and early symptoms of precursors to more serious conditions, including cancerous cells.

Upon detection, the patient can then be referred to further professional analysis and diagnosis.

Westhouse Medical Services chief executive Jack Kaye said BreastCheck will be available for both hospital and home use, further reducing the strain on already-stretched healthcare budgets and hospital staff.